UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

Juvenile dermatomyositis: novel treatment approaches and outcomes

Varnier, GC; Pilkington, CA; Wedderburn, LR; (2018) Juvenile dermatomyositis: novel treatment approaches and outcomes. Current Opinion in Rheumatology , 30 (6) pp. 650-654. 10.1097/BOR.0000000000000538. Green open access

[thumbnail of Wedderburn VarnierPilkingtonWedderburnJDM 19June SUBMITTED.pdf]
Preview
Text
Wedderburn VarnierPilkingtonWedderburnJDM 19June SUBMITTED.pdf - Accepted Version

Download (573kB) | Preview

Abstract

PURPOSE OF REVIEW: The aim of this article is to provide a summary of the recent therapeutic advances and the latest research on outcome measures for juvenile dermatomyositis (JDM). RECENT FINDINGS: Several new international studies have developed consensus-based guidelines on diagnosis, outcome measures and treatment of JDM to standardize and improve patient care. Myositis-specific antibodies together with muscle biopsy histopathology may help the clinician to predict disease outcome. A newly developed MRI-based scoring system has been developed to standardize the use of MRI in assessing disease activity in JDM. New data regarding the efficacy and safety of rituximab, especially for skin disease, and cyclophosphamide in JDM support the use of these medications for severe refractory cases. SUMMARY: International network studies, new biomarkers and outcome measures have led to significant progress in understanding and managing the rare inflammatory myositis conditions such as JDM.

Type: Article
Title: Juvenile dermatomyositis: novel treatment approaches and outcomes
Location: United States
Open access status: An open access version is available from UCL Discovery
DOI: 10.1097/BOR.0000000000000538
Publisher version: https://doi.org/10.1097/BOR.0000000000000538
Language: English
Additional information: This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions.
Keywords: advanced treatment, juvenile dermatomyositis, outcome measures
UCL classification: UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > UCL GOS Institute of Child Health
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > UCL GOS Institute of Child Health > Infection, Immunity and Inflammation Dept
URI: https://discovery.ucl.ac.uk/id/eprint/10054866
Downloads since deposit
279Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item